Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
Primary Purpose
Diabetes Mellitus, Type 2
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
PL2200 Aspirin Capsules
Immediate-Release Aspirin Tablets
Enteric-coated aspirin caplets
Sponsored by

About this trial
This is an interventional prevention trial for Diabetes Mellitus, Type 2
Eligibility Criteria
Inclusion Criteria:
- Adults 21-79
- Body mass index (BMI) of 30-40 kg/m2
- Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of > 6.4% and/or fasting plasma glucose of >125 mg/dL or current anti-diabetic medication)
- AA-induced platelet aggregation response of >60% within 3 hours prior to initial dose of study drug administration
Exclusion Criteria:
- Contraindications to aspirin
- Previous history of vascular disease
- Patient requires insulin
- Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization
Sites / Locations
- MedPace Clinical Pharmacology
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Active Comparator
Active Comparator
Arm Label
PL2200 Aspirin Capsules
Immediate-Release Aspirin Tablets
Enteric-coated aspirin caplets
Arm Description
Investigational drug arm; crossover design
Active comparator; crossover design
Active comparator; crossover design
Outcomes
Primary Outcome Measures
Time to 99% Inhibition of Serum Thromboxane (TxB2)
Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01515657
Brief Title
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
Official Title
A Randomized, Actively Controlled, Crossover Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Patients With Type II Diabetes
Study Type
Interventional
2. Study Status
Record Verification Date
February 2016
Overall Recruitment Status
Completed
Study Start Date
January 2012 (undefined)
Primary Completion Date
June 2012 (Actual)
Study Completion Date
June 2012 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
PLx Pharma
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This study will determine if aspirin from PL2200, an investigational product, gets into the blood stream as quickly as plain aspirin and enteric coated aspirin, and to test whether PL2200 is able to prevent blood clots as effectively as these other products, when administered to patients with diabetes.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes Mellitus, Type 2
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 3
Interventional Study Model
Crossover Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
40 (Actual)
8. Arms, Groups, and Interventions
Arm Title
PL2200 Aspirin Capsules
Arm Type
Experimental
Arm Description
Investigational drug arm; crossover design
Arm Title
Immediate-Release Aspirin Tablets
Arm Type
Active Comparator
Arm Description
Active comparator; crossover design
Arm Title
Enteric-coated aspirin caplets
Arm Type
Active Comparator
Arm Description
Active comparator; crossover design
Intervention Type
Drug
Intervention Name(s)
PL2200 Aspirin Capsules
Intervention Description
325 mg aspirin; once per day for 3 days
Intervention Type
Drug
Intervention Name(s)
Immediate-Release Aspirin Tablets
Intervention Description
325 mg aspirin; once per day for 3 days
Intervention Type
Drug
Intervention Name(s)
Enteric-coated aspirin caplets
Intervention Description
325 mg aspirin; once per day for 3 days
Primary Outcome Measure Information:
Title
Time to 99% Inhibition of Serum Thromboxane (TxB2)
Description
Aspirin's antiplatelet activity is measured by the capacity of platelets to generate serum thromboxane (a surrogate marker for inhibition of COX-1 by aspirin). Inhibition of serum thromboxane is a key marker of antiplatelet efficacy.
Time Frame
4 days
10. Eligibility
Sex
All
Minimum Age & Unit of Time
21 Years
Maximum Age & Unit of Time
79 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Adults 21-79
Body mass index (BMI) of 30-40 kg/m2
Non-insulin-dependent type-2 diabetics (as confirmed by hemoglobin A1c (HbA1c) of > 6.4% and/or fasting plasma glucose of >125 mg/dL or current anti-diabetic medication)
AA-induced platelet aggregation response of >60% within 3 hours prior to initial dose of study drug administration
Exclusion Criteria:
Contraindications to aspirin
Previous history of vascular disease
Patient requires insulin
Use of non-steroidal anti-inflammatory drugs, anti-secretory agents, antacids, and salicylate-containing nutritional supplements within 2 weeks of randomization
Facility Information:
Facility Name
MedPace Clinical Pharmacology
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45212
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
28089180
Citation
Bhatt DL, Grosser T, Dong JF, Logan D, Jeske W, Angiolillo DJ, Frelinger AL 3rd, Lei L, Liang J, Moore JE, Cryer B, Marathi U. Enteric Coating and Aspirin Nonresponsiveness in Patients With Type 2 Diabetes Mellitus. J Am Coll Cardiol. 2017 Feb 14;69(6):603-612. doi: 10.1016/j.jacc.2016.11.050. Epub 2017 Jan 11.
Results Reference
derived
Learn more about this trial
Pharmacodynamic Evaluation of PL2200 Versus Enteric-Coated and Immediate Release Aspirin in Diabetic Patients
We'll reach out to this number within 24 hrs